- Research
- 2022-2026 Research Strategy
- Open Clinical Trials
- Closed Clinical Trials
- What is a Clinical Trial?
- Why Participate in a Clinical Trial
- Research Achievements
- Publications
- Research Development and Funding
- Participating Intitutions
- International Collaboration
- BCT Trials & Projects Summary
- Translational Research
- Clinical Fellowship Program
- International Fellowship Support
- Annual Scientific Meeting
- Travel Grants and Awards
- About
- Our Impact
- Fundraise
- Donate
- Researcher Login
- Cart
ALTTO
Early Breast Cancer
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
ANZ 0601
Metastatic
A randomised phase II trial of double-blind, placebo controlled AMG 706 in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with…
ANZ 7801
Metastatic
Phase III randomised trial to compare endocrine treatment (oophorectomy) versus cytotoxic chemotherapy (adriamycin plus cyclophosphamide) versus oophorectomy plus cytotoxic chemotherapy in…
ANZ 7802
Metastatic
Phase III trial to evaluate hormone therapy (tamoxifen) versus cytotoxic chemotherapy (adriamycin plus cyclophosphamide) versus hormone therapy plus cytotoxic chemotherapy as first line therapy in…
ANZ 8101
Metastatic
Phase III trial to evaluate continuous versus intermittent combination chemotherapy in advanced breast cancer.
ANZ 8102
Metastatic
Phase III trial to evaluate optimal endocrine treatment with oophorectomy and tamoxifen in premenopausal patients with advanced breast cancer.
ANZ 8613
Metastatic
Phase III trial to evaluate addition versus substitution endocrine therapy in advanced breast cancer.
ANZ 8614
Metastatic
Phase III randomised trial to evaluate single agent (MTZ) versus combination (CMFp) cytotoxic therapy in advanced breast cancer.
ANZ 8615
Metastatic
Pilot phase III randomised comparison of cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFp) versus CMFp rapidly alternating with doxorubicin and vincristine (CMFp/AV) in patients…
ANZ 8811
Metastatic
Phase III trial to compare the efficacy of ovarian suppression treatment with LH-RH agonist, goserelin (Zoladex), versus combined Zoladex plus anti-oestrogen therapy, Nolvadex (tamoxifen), in pre and…
ANZ 9002
Early Breast Cancer
A study to compare the efficacy of additional tamoxifen, radiotherapy to the breast, or both treatments, with no additional treatment following complete surgical excision of ductal carcinoma in situ…
ANZ 9311
Metastatic
Comparison of high dose chemotherapy plus filgrastim with standard dose chemotherapy in patients with advanced breast cancer.